Denmark-based healthcare giant Novo Nordisk A/S (NYSE: NVO) has announced the official market launch of semaglutide in China for long-term weight management. Globally, Novo Nordisk markets the glucagon-like peptide-1 receptor agonist (GLP-1RA) under the trade name Wegovy for weight loss, expanding access to this treatment for individuals seeking to manage their weight effectively.
Global Clinical Studies and Validation
The STEP series of global large-scale clinical studies for semaglutide included approximately 25,000 overweight and obese subjects, providing robust validation of the molecule’s efficacy, safety, and other health benefits in long-term adult weight management. The results demonstrated that semaglutide outperformed placebo in terms of efficacy, clinical significance, and sustained weight loss, with an average weight loss of 17% (16.8kg) over a period of 16 months.
Impact on Hunger and Satiety
In obese patients, semaglutide has been shown to help reduce hunger, increase satiety, and decrease food cravings, thereby reducing calorie intake and promoting weight loss. This impact on appetite regulation is a significant factor in the drug’s weight management efficacy.
Advanced Drug Delivery Technology
Semaglutide features a half-life extended to 7 days through genetic recombination technology, allowing for once-weekly administration. This convenience, combined with up to 94% homology with human GLP-1, positions semaglutide as a leading option for weight management, offering both efficacy and ease of use.-Fineline Info & Tech
Leave a Reply